Leap Therapeutics Inc
LPTX2.050USD
0.000
收盘 12/19, 16:00（美东）报价延迟15分钟
84.95M总市值
亏损市盈率 TTM
关于 Leap Therapeutics Inc 公司
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Inc简介
公司代码LPTX
公司名称Leap Therapeutics Inc
上市日期Jan 24, 2017
CEOOnsi (Douglas E)
员工数量52
证券类型Ordinary Share
年结日Jan 24
公司地址47 Thorndike Street
城市CAMBRIDGE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02142
电话16172524343
网址https://www.leaptx.com/
公司代码LPTX
上市日期Jan 24, 2017
CEOOnsi (Douglas E)
Leap Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
140.87K
+30.09%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.05K
--
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Mr. Khing Oei
Mr. Khing Oei
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William (Wil) Mcevoy
Mr. William (Wil) Mcevoy
Chief Investment Officer, Director
Chief Investment Officer, Director
--
--
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
140.87K
+30.09%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.05K
--
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Mr. Khing Oei
Mr. Khing Oei
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 9 小时前
更新时间: 9 小时前
持股股东
股东类型
持股股东
持股股东
占比
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
BofA Global Research (US)
2.55%
Acadian Asset Management LLC
2.18%
其他
60.66%
持股股东
持股股东
占比
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
BofA Global Research (US)
2.55%
Acadian Asset Management LLC
2.18%
其他
60.66%
股东类型
持股股东
占比
Family Office
14.62%
Corporation
11.53%
Individual Investor
10.99%
Investment Advisor
6.90%
Investment Advisor/Hedge Fund
3.10%
Research Firm
2.88%
Venture Capital
1.25%
Hedge Fund
0.35%
Bank and Trust
0.01%
其他
48.38%
机构持股
更新时间: 10月5日 周日
更新时间: 10月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q3
109
9.06M
16.46%
-11.77M
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
2023Q2
173
10.09M
52.77%
+1.83M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Gilead Sciences Inc
5.32M
12.84%
--
--
Jun 30, 2025
Acadian Asset Management LLC
1.24M
2.99%
-43.42K
-3.39%
Jun 30, 2025
Beigene Ltd
1.22M
2.93%
+1.22M
--
Oct 31, 2024
The Vanguard Group, Inc.
1.16M
2.8%
-14.92K
-1.27%
Jun 30, 2025
Hightower Advisors, LLC
1.10M
2.65%
+1.05M
+2071.98%
Jun 30, 2025
Simplify Asset Management Inc
857.36K
2.07%
-93.61K
-9.84%
Jun 30, 2025
HealthCare Ventures LLC
697.23K
1.68%
+20.91K
+3.09%
Apr 21, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Simplify Health Care ETF
0.37%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Simplify Health Care ETF
占比0.37%
iShares Micro-Cap ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
公告日期
类型
比率
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
常见问题
Leap Therapeutics Inc的前五大股东是谁？
Leap Therapeutics Inc 的前五大股东如下：
Gilead Sciences Inc持有股份：5.32M，占总股份比例：12.84%。
Acadian Asset Management LLC持有股份：1.24M，占总股份比例：2.99%。
Beigene Ltd持有股份：1.22M，占总股份比例：2.93%。
The Vanguard Group, Inc.持有股份：1.16M，占总股份比例：2.80%。
Hightower Advisors, LLC持有股份：1.10M，占总股份比例：2.65%。
Gilead Sciences Inc持有股份：5.32M，占总股份比例：12.84%。
Acadian Asset Management LLC持有股份：1.24M，占总股份比例：2.99%。
Beigene Ltd持有股份：1.22M，占总股份比例：2.93%。
The Vanguard Group, Inc.持有股份：1.16M，占总股份比例：2.80%。
Hightower Advisors, LLC持有股份：1.10M，占总股份比例：2.65%。
Leap Therapeutics Inc的前三大股东类型是什么？
Leap Therapeutics Inc 的前三大股东类型分别是：
Winklevoss Capital Management, LLC
Severns (Sean Michael)
Gilead Sciences Inc
Winklevoss Capital Management, LLC
Severns (Sean Michael)
Gilead Sciences Inc
有多少机构持有Leap Therapeutics Inc(LPTX)的股份？
截至2025Q3，共有109家机构持有Leap Therapeutics Inc的股份，合计持有的股份价值约为9.06M，占公司总股份的16.46%。与2025Q2相比，机构持股有所增加，增幅为-28.66%。
哪个业务部门对Leap Therapeutics Inc的收入贡献最大？
在--，--业务部门对Leap Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
